Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription Articles published in J Clin Invest Retrieve available abstracts of 43 articles: HTML format

Single Articles

October 2024
1. KUMAR A, Goel H, Wisniewski C, Wang T, et al
   Neuropilin-2 expressing cells in breast cancer are S-nitrosylation hubs that mitigate radiation-induced oxidative stress.
   J Clin Invest. 2024 Oct 1:e181368. doi: 10.1172/JCI181368.
   PubMed     Abstract available
   
   
   September 2024
2. WINKLER J, Tan W, Diadhiou CM, McGinnis CS, et al
   Single-cell analysis of breast cancer metastasis reveals epithelial-mesenchymal plasticity signatures associated with poor outcomes.
   J Clin Invest. 2024;134:e164227.
   PubMed     Abstract available
   
   
   
3. REEVES MQ
   Mapping the transcriptional evolution of human metastatic breast cancer.
   J Clin Invest. 2024;134:e183971.
   PubMed     Abstract available
   
   
   August 2024
4. SHEN Y, Yan J, Li L, Sun H, et al
   LOXL2-induced PEAR1 Ser891 phosphorylation suppresses CD44 degradation and promotes triple-negative breast cancer metastasis.
   J Clin Invest. 2024;134:e177357.
   PubMed     Abstract available
   
   
   May 2024
5. MARCHESE E, Demehri S
   Posttranslational protein modifications as gatekeepers of cancer immunogenicity.
   J Clin Invest. 2024;134:e180914.
   PubMed     Abstract available
   
   
   April 2024
6. JOHNSON N
   Surviving without BRCA2: MLH1 gets R-looped in to curtail genomic instability.
   J Clin Invest. 2024;134:e179325.
   PubMed     Abstract available
   
   
   March 2024
7. ZHU Y, Banerjee A, Xie P, Ivanov AA, et al
   Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
   J Clin Invest. 2024;134:e176390.
   PubMed     Abstract available
   
   
   February 2024
8. LI Z, Metzger Filho O, Viale G, dell'Orto P, et al
   HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.
   J Clin Invest. 2024 Feb 1:e176454. doi: 10.1172/JCI176454.
   PubMed     Abstract available
   
   
   January 2024
9. LUO M, Bao L, Xue Y, Zhu M, et al
   ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2.
   J Clin Invest. 2024;134:e171166.
   PubMed     Abstract available
   
   
   
10. PEYVANDI S, Bulliard M, Yilmaz A, Kauzlaric A, et al
    Tumor-educated Gr1+CD11b+ cells drive breast cancer metastasis via OSM/IL6-JAK-induced cancer cell plasticity.
    J Clin Invest. 2024 Jan 18:e166847. doi: 10.1172/JCI166847.
    PubMed     Abstract available
    
    
    December 2023
11. FARES J, Petrosyan E, Kanojia D, Dmello C, et al
    Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases.
    J Clin Invest. 2023;133:e161142.
    PubMed     Abstract available
    
    
    November 2023
12. LI M, Nishimura T, Takeuchi Y, Hongu T, et al
    FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters.
    J Clin Invest. 2023;133:e166666.
    PubMed     Abstract available
    
    
    October 2023
13. KINA E, Laverdure JP, Durette C, Lanoix J, et al
    Breast cancer immunopeptidomes contain numerous shared tumor antigens.
    J Clin Invest. 2023 Oct 31:e166740. doi: 10.1172/JCI166740.
    PubMed     Abstract available
    
    
    
14. IRANI S, Tan W, Li Q, Toy W, et al
    Somatic estrogen receptor alpha mutations that induce dimerization promote receptor activity and breast cancer proliferation.
    J Clin Invest. 2023 Oct 26:e163242. doi: 10.1172/JCI163242.
    PubMed     Abstract available
    
    
    
15. ZHAO N, Kabotyanski EB, Saltzman AB, Malovannaya A, et al
    Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.
    J Clin Invest. 2023 Oct 24:e172503. doi: 10.1172/JCI172503.
    PubMed     Abstract available
    
    
    
16. XIONG SY, Wen HZ, Dai LM, Lou YX, et al
    A brain-tumor neural circuit controls breast cancer progression in mice.
    J Clin Invest. 2023 Oct 17:e167725. doi: 10.1172/JCI167725.
    PubMed     Abstract available
    
    
    September 2023
17. CHANG HL, Schwettmann B, McArthur HL, Chan IS, et al
    Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response.
    J Clin Invest. 2023;133:e172156.
    PubMed     Abstract available
    
    
    
18. BAO L, Kumar A, Zhu M, Peng Y, et al
    SAP30 promotes breast tumor progression by bridging the transcriptional corepressor SIN3 complex and MLL1.
    J Clin Invest. 2023;133:e168362.
    PubMed     Abstract available
    
    
    July 2023
19. DEVARAJAN R, Izzi V, Peltoketo H, Rask G, et al
    Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models.
    J Clin Invest. 2023 Jul 27:e159181. doi: 10.1172/JCI159181.
    PubMed     Abstract available
    
    
    
20. YANG M, Li Y, Kong L, Huang S, et al
    Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer.
    J Clin Invest. 2023;133:e164428.
    PubMed     Abstract available
    
    
    June 2023
21. LIN Q, Liu T, Wang X, Hou G, et al
    Long noncoding RNA HITT coordinates with RGS2 to inhibit PD-L1 translation in T cell immunity.
    J Clin Invest. 2023;133:e162951.
    PubMed     Abstract available
    
    
    April 2023
22. BERTOLINI I, Perego M, Nefedova Y, Lin C, et al
    Intercellular hif1alpha reprograms mammary progenitors and myeloid immune evasion to drive high-risk breast lesions.
    J Clin Invest. 2023;133:e164348.
    PubMed     Abstract available
    
    
    March 2023
23. ZHENG C, Wei Y, Zhang P, Xu L, et al
    CRISPR/Cas9 screen uncovers functional translation of cryptic lncRNA-encoded open reading frames in human cancer.
    J Clin Invest. 2023;133:e159940.
    PubMed     Abstract available
    
    
    February 2023
24. NANDI I, Smith HW, Sanguin-Gendreau V, Ji L, et al
    Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression.
    J Clin Invest. 2023 Feb 16:e162324. doi: 10.1172/JCI162324.
    PubMed     Abstract available
    
    
    December 2022
25. COLLIGAN SH, Amitrano AM, Zollo RA, Peresie J, et al
    Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression.
    J Clin Invest. 2022;132:e158661.
    PubMed     Abstract available
    
    
    
26. HORVAT NK, Lesinski GB
    Bring on the brequinar: an approach to enforce the differentiation of myeloid-derived suppressor cells.
    J Clin Invest. 2022;132:e165506.
    PubMed     Abstract available
    
    
    October 2022
27. ARAUJO AM, Abaurrea A, Azcoaga P, Lopez-Velazco JI, et al
    Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment.
    J Clin Invest. 2022;132.
    PubMed    
    
    
    
28. SHARMA S, Opyrchal M, Lu X
    Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression?
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    August 2022
29. WANG J, Wang Q, Guan Y, Sun Y, et al
    Breast cancer cell-derived microRNA-155 suppresses tumor progression via enhancing immune cell recruitment and anti-tumor function.
    J Clin Invest. 2022 Aug 4. pii: 157248. doi: 10.1172/JCI157248.
    PubMed     Abstract available
    
    
    June 2022
30. LU Z, Mao W, Yang H, Santiago-O'Farrill JM, et al
    SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    May 2022
31. SZCZEPANIAK P, Siedlinski M, Hodorowicz-Zaniewska D, Nosalski R, et al
    Breast cancer chemotherapy induces vascular dysfunction and hypertension through NOX4 dependent mechanism.
    J Clin Invest. 2022 May 26. pii: 149117. doi: 10.1172/JCI149117.
    PubMed     Abstract available
    
    
    April 2022
32. WAARTS MR, Stonestrom AJ, Park YC, Levine RL, et al
    Targeting mutations in cancer.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    March 2022
33. HUANG C, Hu F, Song D, Sun X, et al
    EZH2-triggered methylation of SMAD3 promotes its activation and tumor metastasis.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    
34. ABU-LIBDEH B, Jhujh SS, Dhar S, Sommers JA, et al
    RECON syndrome is a genome instability disorder caused by mutations in the DNA helicase RECQL1.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    
35. SUN S, Brazhnik K, Lee M, Maslov AY, et al
    Single-cell analysis of somatic mutation burden in mammary epithelial cells of pathogenic BRCA1/2 mutation carriers.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    February 2022
36. ARAUJO AM, Abaurrea A, Azcoaga P, Lopez-Velazco JI, et al
    Stromal Oncostatin M cytokine promotes breast cancer progression by reprogramming the tumour microenvironment.
    J Clin Invest. 2022 Feb 22. pii: 148667. doi: 10.1172/JCI148667.
    PubMed     Abstract available
    
    
    January 2022
37. YUE Z, Niu X, Yuan Z, Qin Q, et al
    RSPO2 and RANKL signal through LGR4 to regulate osteoclastic premetastatic niche formation and bone metastasis.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    
38. XU J, Su SM, Zhang X, Chan UI, et al
    ATP11B inhibits breast cancer metastasis in a mouse model by suppressing externalization of non-apoptotic phosphatidylserine.
    J Clin Invest. 2022 Jan 13. pii: 149473. doi: 10.1172/JCI149473.
    PubMed     Abstract available
    
    
    December 2021
39. RAE JM, Lippman ME
    The role of estrogen receptor signaling in suppressing the immune response to cancer.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    
40. KISHIKAWA T, Higuchi H, Wang L, Panch N, et al
    WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    November 2021
41. EL-HOUJEIRI L, Biondini M, Paquette M, Kuasne H, et al
    Folliculin impairs breast tumor growth by repressing TFE3-dependent induction of the Warburg effect and angiogenesis.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    March 2021
42. MUSCARELLA AM, Aguirre S, Hao X, Waldvogel SM, et al
    Exploiting bone niches: progression of disseminated tumor cells to metastasis.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    
43. KARTHIKEYAN S, Waters IG, Dennison L, Chu D, et al
    Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.